WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005117545) NITRIC OXIDE DIOXYGENASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/117545    International Application No.:    PCT/US2005/018464
Publication Date: 15.12.2005 International Filing Date: 26.05.2005
IPC:
A61K 8/02 (2006.01), A61K 31/74 (2006.01), A01N 59/00 (2006.01)
Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnete Avenue, Cincinnati, OH 45229 (US) (For All Designated States Except US).
GARDNER, Paul, R. [US/US]; (US) (For US Only)
Inventors: GARDNER, Paul, R.; (US)
Agent: LYMAN, Beverly, A.; Wood, Herron & Evans, L.L.P., 2700 Carew Tower, Cincinnati, OH 45202 (US)
Priority Data:
60/574,807 27.05.2004 US
Title (EN) NITRIC OXIDE DIOXYGENASE INHIBITORS
(FR) INHIBITEURS DE LA DIOXYGENASE DE MONOXYDE D'AZOTE
Abstract: front page image
(EN)A method and composition to inhibit the enzyme nitric oxide dioxygenase (NOD) and therefore accumulate nitric oxide (NO) in cells or tissues. By preventing NO removal, the inhibitors may effect cellular signaling, modulate vasotension, enhance O2 delivery to tissues, and provide antibiotic and/or antineoplastic effects. Inhibitors include compounds that bind to the iron in the heme portion of NOD, and include allicin and azotes.
(FR)L'invention concerne une méthode et une composition permettant d'inhiber l'enzyme appelée dioxygénase de monoxyde d'azote (NOD) et, par conséquent, d'accumuler le monoxyde d'azote (NO) dans des cellules ou des tissus. En prévenant la suppression du monoxyde d'azote, ces inhibiteurs permettent d'effectuer une signalisation cellulaire, de moduler la tension vasculaire, d'améliorer la distribution de O2 dans les tissus et de produire des effets antibiotiques et/ou antinéoplasiques. Ces inhibiteurs comprennent des composés qui se lient au fer dans la partie hémique du monoxyde d'azote et comprennent de l'allicine et des azotes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)